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valuing beneﬁts concerned with avoiding amputation
twice less than physicians. Anyway the price of
prostagladin E1 is about 350 USD for a period of treat-
ment that is much less than the median sum of money
named by both groups of respondents.
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Hypothermia resulting from invasive surgical procedures
can increase blood and ﬂuid loss and complicate the 
post-operative course of recovery. Therefore, hypother-
mia can be quite costly to treat. The Arctic SunTM Model
100 is new a non-invasive perioperative warming device,
which controls body temperature through single use
Arctic Sun Energy Transfer PadsTM regulated by a control
module.
OBJECTIVE: To compare the initial surgical and inten-
sive care unit (ICU) outcomes and costs resulting from
use of the Arctic Sun vs. standard care of temperature
management in patients undergoing off-pump coronary
artery bypass (OPCAB) surgery. 
METHODS: Data from two clinical studies conducted at
a major university were combined with other published
data to compare surgical outcomes and treatment costs
to the hospital associated with patient re-warming
methods.
RESULTS: Preliminary ﬁndings in OPCAB procedures
indicate post-operative hypothermia incidence is lower
for patients using the Arctic SunTM Model 100 (5% n =
58) compared to patients warmed using the standard
warming methods (48%, n = 48). An additional cost of
over $338.00 per patient for blood products and ﬂuids
received by patients was incurred for the standard care
population compared to the Arctic SunTM population.
Compared to normothermic patients, patients who are
hypothermic have an average increased hospital stay of
5.8 days ($2,616.96), and an average increased ICU time
of 4.2 hours ($236.88). Combining these costs with the
costs to treat infections, morbid cardiac events, and addi-
tional lab work, the total additional costs for complica-
tions due to hypothermia can easily exceed $8,270 per
patient. 
CONCLUSION: The Arctic SunTM is an effective tem-
perature management device for OPCAB patients. Com-
bining the Arctic SunTM clinical data with published
economic data suggests that the Arctic SunTM for tem-
perature management in OPCAB procedures could save
over $33,800 in blood product costs and over $355,000
in complication costs per 100 patients.
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OBJECTIVE: Patients on long-term anticoagulation
requiring interruption of therapy for a surgical procedure
historically have been hospitalized to receive “bridging
therapy” with continuous infusion intravenous unfrac-
tionated heparin (UFH). Recently, low-molecular weight
heparins such as enoxaparin have been reported to have
comparable safety and efﬁcacy in this indication, and can
be administered on an outpatient basis. The objective of
this study was to compare the costs of bridging therapy
with enoxaparin versus UFH in this patient population. 
METHODS: We conducted a cost-minimization analysis
of bridging therapy from the perspective of a third-party
health insurer. Patient treatment protocols were set forth
to reﬂect current clinical practice. Bridging therapy was
assumed to take place over an eight-day period, reﬂect-
ing three preoperative days, one day of surgery, and four
postoperative days. Three alternative bridging strategies
were considered: (1) UFH 30,000 units/day administered
in hospital; (2) enoxaparin 1.0mg/kg self-administered
twice-daily by the patient at home; and (3) enoxaparin
1.5mg/kg administered once-daily in the patient’s home
by a visiting nurse. Various secondary sources were 
used to estimate the costs of drug acquisition, ancillary
supplies, provider services, and hospitalization. Analyses
were performed for day surgery, surgery requiring
overnight stay, and surgery requiring a stay of 4+ days.
RESULTS: Bridging therapy with UFH in hospital costs
$4,397 per patient for day surgery, $3,818 for procedures
requiring an overnight stay, and $2,080 for procedures
requiring a stay of 4+ days (2001 US$). Corresponding
cost estimates for patient-administered enoxaparin are
$663, $673, and $743. Cost estimates for nurse-
administered enoxaparin are $990, $935, and $771,
respectively.
CONCLUSIONS: Bridging therapy with enoxaparin 
at home whether patient-administered or nurse-
administered is substantially less costly than bridging
with UFH in hospital. The magnitude of cost savings is
highest for day surgery and lowest for surgeries requiring
a prolonged recovery in hospital.
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